Aspirin Plus Vitamin C vs Chemo: A Rat Study, Not a Trial

An Instagram post from @analyzeandoptimize, posted around October 16, 2026, says that compared with doxorubicin ("standard chemo"), aspirin plus IV vitamin C better restored liver structure and function, gave "visibly smaller tumors," lowered the tumor markers AFP and CA19.9, lowered inflammation (IL-6, TNF-α), restored p53, and was "over 3x more toxic to cancer cells than healthy cells" in cell studies. The post cites no study.

View the original post

What the real study is

The details match a 2023 paper in BMC Cancer: "Biochemical and pathophysiological improvements in rats with thioacetamide induced-hepatocellular carcinoma using aspirin plus vitamin C" (PubMed 36809998). The authors are at Damietta University in Egypt. We could not confirm that the post is based on this paper, but the markers (AFP, CA19.9, IL-6, TNF-α, p53) and the "over 3x" figure match it closely.

The study used 48 male rats in four groups of 12: healthy, liver cancer with no treatment, liver cancer treated with doxorubicin, and liver cancer treated with aspirin plus vitamin C. Liver cancer was induced with a chemical. The researchers also tested a human liver cancer cell line (HepG-2) and normal human lung cells (WI-38) in dishes.

What's real

The paper does report the results the post lists. Per the paper, the liver cancer markers AFP and CA19.9 fell with treatment, and the authors say the biggest improvement was in the aspirin plus vitamin C group. p53 fell in untreated cancer rats and rose with treatment. The cell result is also in the paper: a selectivity index of 3.663 for the combination and 0.819 for doxorubicin. That index is the dose that harms normal cells divided by the dose that harms cancer cells. A value under 1 means the drug harmed the normal cells at a lower dose than the cancer cells in that test.

What's missing or wrong

These are rats and cells, not people. Nothing in this study was done in humans. The post does not say so.

"Visibly smaller tumors." The paper reports no tumor measurements, counts or volumes. It judged tumor burden from the look of the liver surface, tissue under the microscope and blood markers. The post's wording goes beyond what we found.

"IV vitamin C." In the rats, vitamin C was injected into the abdomen (intraperitoneal) at 4 g per kg of body weight per day, with aspirin by mouth at 60 mg per kg per day. That is not the same as an IV drip in a person. These are animal doses and are not doses for people. Any dose that is right for you is set by your own care team.

The cell test used one cancer line and one normal cell type, and the normal cells were lung cells, not liver cells. One comparison is not proof that a treatment will spare healthy tissue in a body.

"Standard chemo." NCI's liver cancer treatment summary lists immunotherapy and targeted drugs as the standard systemic treatments for advanced hepatocellular carcinoma. It mentions doxorubicin only as a drug given into the liver's artery during chemoembolization. It also says no evidence supports a survival benefit from cytotoxic chemotherapy given through the blood for advanced disease compared with no treatment or supportive care. So doxorubicin is not the standard that new treatments are usually measured against.

Limits the paper itself has. There was no aspirin-only or vitamin C-only group, so the study could not show that the two drugs work together. Toxicity was monitored, but we found no results reported. The authors say other animal models and longer studies are needed. It was a single research group's work, and the authors declare no competing interests.

What the evidence says in people

NCI says high-dose IV vitamin C has been generally well tolerated in trials but the FDA has not approved it as a cancer treatment, and human studies have had design limitations. A 2024 randomized trial in prostate cancer found that adding IV vitamin C to docetaxel did not improve outcomes, according to NCI. NCI also notes that in a mouse study, one form of vitamin C given before doxorubicin led to larger tumors than doxorubicin alone. Kidney problems after vitamin C have been reported in people with existing kidney disease. See our articles on high-dose vitamin C and our earlier news piece Cancer Myth in the News: High-Dose Vitamin C Cure Claims.

For aspirin, NCI says the chief concern is gastrointestinal bleeding. The research on aspirin focuses on lowering risk of some cancers, mainly colorectal, not treating liver cancer. See aspirin and cancer risk. We found no human trial of aspirin plus vitamin C against liver cancer.

The sales funnel

The caption asks readers to comment "PRISM" to get twice-weekly study breakdowns and supplement deep dives, and to click a bio link for a free consult. We could not see what the consult involves, and we are not saying anything about the poster's intent. We note it so readers know the post leads to a service, and that a study summary in a marketing post is worth checking against the paper.

What to do with this

Do not replace chemotherapy or any treatment your team recommends with supplements. Before taking aspirin or vitamin C during cancer treatment, ask your oncology team. Aspirin can raise bleeding risk, and some chemotherapy also lowers platelets. Supplements can interact with treatment. Read more in are supplements safe during cancer treatment and liver cancer treatment.

If you have a fever of 100.4 F (38 C) or higher during cancer treatment, call your care team right away. For emergencies, call 911.

Sources

• Instagram post (@analyzeandoptimize): instagram.com
• El Sadda RR, Elshahawy ZR, Saad EA, BMC Cancer 2023;23:175, PubMed record: pubmed.ncbi.nlm.nih.gov
• Same paper, full text: pmc.ncbi.nlm.nih.gov
• National Cancer Institute, "Vitamin C (PDQ), Health Professional": cancer.gov
• National Cancer Institute, "Can Taking Aspirin Help Prevent Cancer?": cancer.gov
• National Cancer Institute, "Adult Primary Liver Cancer Treatment (PDQ), Health Professional": cancer.gov

How this article was prepared

An AI-assisted editorial system helped prepare this page. It used the PubMed record and full text of the rat study and NCI pages that we opened on October 31, 2026. We read only the first part of the two long NCI pages. We could not view the Instagram post itself, so we rely on the caption as supplied to us. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.